Case Report: A case of rapamycin-eluting stent for the treatment of refractory stenosis of arteriovenous fistula stenosis

Case Report: A case of rapamycin-eluting stent for the treatment of refractory stenosis of arteriovenous fistula stenosis

Blog Article

For patients with repeated stenosis of autologous arteriovenous fistula, percutaneous transluminal angioplasty (PTA) An inexact multiple-recourse hybrid-fuel management model with considering carbon reduction requirement for a biofuel-penetrated heating system or bare metal stent placement had limited efficacy.Rapamycin was reported to inhibit neointimal hyperplasia and keep blood vessels patent.In this study, we reported a case with refractory stenosis, i.e., a short duration of patency maintenance after each repeated PTA, which was treated with a rapamycin-eluting stent (RES).

The RES extended the patency duration from Cytotoxic Immune Response to a Xenogeneic Bioartificial Liver 4 to 5 months on average to 14 months.The stent was used to maintain dialysis for over 30 months.RES may be an effective way to treat refractory stenosis and salvage limited vascular resources.